Immunotherapeutic agents

Details Immunotherapeutic agents Immunotherapeutic agents

1995-12-26

1998-03-17

Shah, Mukund J.

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

548477, 548479, 546142, 514417, 514416, 514309, C07D20948, C07D20946, C07D21724, A61K 3140

Patent

active

057288445

ABSTRACT:
Novel amides are inhibitors of TNF.alpha. and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3-phthalimido-3-(3-cyclopentyloxy-4-methoxyphenyl)propionamide.

REFERENCES:
patent: 5512682 (1996-04-01), Hilpest
David Cavalla, et al., "Phosphodiesterase IV Inhibitors: Structural Diversity and Therapeutic Potential In Asthma", Current Medical Chemistry, 1995, 2, pp. 561-572.
Louis J. Lombardo, "Phosphodiesterase-IV Inhibitors: Novel Therapeutics for the Treatment of Inflammatory Diseases", Current Pharmaceutical Design, 1995, pp. 255-268.
John A. Lowe, III, et al., "The PDE IV family of calcium-independent phosphodiesterase enzymes", Drugs of the Future, 1992, 17(9):799-807.
Malcolm N. Palfreyman, "Phosphodiesterase type IV inhibitors as antiinflammatory agents", Drugs of the Future, 1995, 20(8):793-804.
Les Sekut, et al., "Pathophysiology and Regulation of TNF-.alpha. in Inflammation", DN&P,9(5), Jun. 1996, pp. 261-269.

Affiliated with

Also associated with

Rating

Immunotherapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunotherapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-958902